Therapeutic potency of oncolytic virotherapy–induced cancer stem cells targeting in brain tumors, current status, and perspectives

Bahreyni, Amirhossein; Ghorbani, Elnaz; Fuji, Hamid; Ryzhikov, Mikhail; Khazaei, Majid; Erfani, Marjan; Hassanian, Seyed Mahdi; Azadmanesh, Kayhan

doi:10.1002/jcb.27661

Cited by 8 publications

(7 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OVs can directly infect and eliminate tumor cells by identifying special biomarkers that are overexpressed on cancer cells like laminin and CD64 or causing immune attack via cytolytic cells indirectly, or both ways together 189,192 (Figure 1). Current data have shown OVs' ability in targeting CSCs in different types of cancers including brain tumors 193 . Accordingly, Gp73‐regulated oncolytic AD exhibited toxic effects on hepatic CSCs and induced apoptosis in vitro and in vivo 194 .…”

Section: Novel Immune‐based Therapeutic Modalities Against Cscsmentioning

confidence: 99%

Update on immune‐based therapy strategies targeting cancer stem cells

Izadpanah,

Mohammadkhani,

Masoudnia

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Accumulating data reveals that tumors possess a specialized subset of cancer cells named cancer stem cells (CSCs), responsible for metastasis and recurrence of malignancies, with various properties such as self‐renewal, heterogenicity, and capacity for drug resistance. Some signaling pathways or processes like Notch, epithelial to mesenchymal transition (EMT), Hedgehog (Hh), and Wnt, as well as CSCs' surface markers such as CD44, CD123, CD133, and epithelial cell adhesion molecule (EpCAM) have pivotal roles in acquiring CSCs properties. Therefore, targeting CSC‐related signaling pathways and surface markers might effectively eradicate tumors and pave the way for cancer survival. Since current treatments such as chemotherapy and radiation therapy cannot eradicate all of the CSCs and tumor relapse may happen following temporary recovery, improving novel and more efficient therapeutic options to combine with current treatments is required. Immunotherapy strategies are the new therapeutic modalities with promising results in targeting CSCs. Here, we review the targeting of CSCs by immunotherapy strategies such as dendritic cell (DC) vaccines, chimeric antigen receptors (CAR)‐engineered immune cells, natural killer‐cell (NK‐cell) therapy, monoclonal antibodies (mAbs), checkpoint inhibitors, and the use of oncolytic viruses (OVs) in pre‐clinical and clinical studies. This review will mainly focus on blood malignancies but also describe solid cancers.

show abstract

Section: Novel Immune‐based Therapeutic Modalities Against Cscsmentioning

confidence: 99%

Update on immune‐based therapy strategies targeting cancer stem cells

Izadpanah,

Mohammadkhani,

Masoudnia

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In cellular and animal experiments, they demonstrated that MYXV destroyed BTIC and increased the survival of BTIC-bearing mice. Furthermore, even in mice with “advanced” BTIC tumors, the combination of MYXV and rapamycin significantly improved MYXV’s antitumor activities [ 98 ]. Akt signaling is essential for cell growth, proliferation, and survival.…”

Section: Oncolytic Virotherapymentioning

confidence: 99%

“…DNX-2401 will be given intratumorally at a dosage of 1.0 mL into the brain tumor as part of this trial. Patients will have intravenous pembrolizumab, 200 mg every 3 weeks for 105 weeks (2 years), after 7 to 9 days (NCT02798406) [ 98 , 109 ]. To encourage selective replication in tumor cells and reduce viral toxicity, the most common change is deleting non-essential viral genes.…”

Section: Genetic Engineering Of Oncolytic Virusesmentioning

confidence: 99%

The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells

Faghihkhorasani,

Dalvand,

Derafsh

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

Cancer Stem Cells (CSCs) are the main “seeds” for the initiation, growth, metastasis, and recurrence of tumors. According to many studies, several viral infections, including the human papillomaviruses, hepatitis B virus, Epstein–Barr virus, and hepatitis C virus, promote the aggressiveness of cancer by encouraging the development of CSC features. Therefore, a better method for the targeted elimination of CSCs and knowledge of their regulatory mechanisms in human carcinogenesis may lead to the development of a future tool for the management and treatment of cancer. Oncolytic viruses (OVs), which include the herpes virus, adenovirus, vaccinia, and reovirus, are also a new class of cancer therapeutics that have favorable properties such as selective replication in tumor cells, delivery of numerous eukaryotic transgene payloads, induction of immunogenic cell death and promotion of antitumor immunity, as well as a tolerable safety profile that essentially differs from that of other cancer therapeutics. The effects of viral infection on the development of CSCs and the suppression of CSCs by OV therapy were examined in this paper. The purpose of this review is to investigate the dual role of viruses in CSCs (oncolytic virotherapy and viral oncogenes). Graphical Abstract

show abstract

“…Targeting CSC by OVs has emerged as a novel and effective strategy for glioma treatment to achieve long-term control. OVs are capable of destructing cancer cells as well as CSC in preclinical data [ 59 ]. Fast-track approval of several OVs (DNX-2401, Toca511, and PVS-RIPO) by the FDA were granted for brain tumors, after they showed durable complete responses in about 20% of patients and rare serious side effects [ 60 ].…”

Section: Oncolytic Virus Therapymentioning

confidence: 99%

Neuroimmune crosstalk and its impact on cancer therapy and research

Sharawy

2022

Discov Onc

View full text Add to dashboard Cite

Cancer is a major health problem as it is the first or second leading cause of death worldwide. The global cancer burden is expected to rise 47% relative to 2020 cancer incidence. Recently, the fields of neuroscience, neuroimmunology and oncology have elaborated the neuroimmune crosstalk role in tumor initiation, invasion, progression, and metastases. The nervous system exerts a broad impact on the tumor microenvironment by interacting with a complex network of cells such as stromal, endothelial, malignant cells and immune cells. This communication modulates cancer proliferation, invasion, metastasis, induce resistance to apoptosis and promote immune evasion. This paper has two aims, the first aim is to explain neuroimmune crosstalk in cancer, tumor innervation origin and peripheral nervous system, exosomes, and miRNA roles. The second aim is to elaborate neuroimmune crosstalk impact on cancer therapy and research highlighting various potential novel strategies such as use of immune checkpoint inhibitors and anti-neurogenic drugs as single agents, drug repurposing, miRNA-based and si-RNA-based therapies, tumor denervation, cellular therapies, and oncolytic virus therapy.

show abstract

Therapeutic potency of oncolytic virotherapy–induced cancer stem cells targeting in brain tumors, current status, and perspectives

Cited by 8 publications

References 63 publications

Update on immune‐based therapy strategies targeting cancer stem cells

Update on immune‐based therapy strategies targeting cancer stem cells

The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells

Neuroimmune crosstalk and its impact on cancer therapy and research

Contact Info

Product

Resources

About